SUBSCRIBE
SUBSCRIBE
Dan Samorodnitsky

Dan Samorodnitsky

News Editor

Dan Samorodnitsky is the news editor at BioSpace. He has a decade of experience covering biotech, genetics and medicine. Before coming to BioSpace he was an editor at Drug Discovery News and Massive Science, and his writing has appeared in outlets such as Quanta, STAT, GROW and many others. He is based in Minneapolis. You can reach him at dan.samorodnitsky@biospace.com.

Different pills on seesaw weight scale. Comparison, choice, healthcare and medicine concept. Flat design. EPS 8 vector illustration, no transparency, no gradients
Cancer
Merck’s Injectable Keytruda Matches IV Formula in Pivotal Trial
Merck’s new formulation of the mega-blockbuster Keytruda, made in collaboration with Alteogen, could help to keep the drug’s patent cliff at bay.
March 28, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
caute cartoon businesspeople stand on hands with blue backgroound
China
Bayer Jumps on Chinese Partnership Train with Oncology Deal
The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of cancers. Financial details of the deal were not disclosed.
March 26, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Podcast
Trump’s Pharma Tariffs, Monarez for CDC, Novo’s New Obesity Play, More
President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC director nominee; Novo Nordisk joins the triple-G race; Alnylam wins approval for Amvuttra in ATTR-CM; and Cassava Sciences ends development of simufilam in Alzheimer’s.
March 26, 2025
 · 
1 min read
 · 
Heather McKenzie
Businessmen working together installing gears in human head, business initiative, mindset improvement concept
Vaccines
GSK Builds on Real-World Experiment to Study Shingrix’s Impact on Dementia
The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” experiment to determine whether 65- and 66-year-olds who received GSK’s shingles vaccine Shingrix have reduced dementia risk.
March 25, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Online Vertebrologist ,Orthopedics Woman traumatologist Surgeon Doctor.Internet Presentation Seminar.Fracture, Pain in Back Spine Diagnostics.Internet Conference. Digital Medical Hospital Illustration
Immunology and inflammation
Hillstar Bio Nets $67M Series A to Advance Autoimmune and Arthritis Pipeline
Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.
March 25, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Vector illustration of a bottle of wine and a glass with red wine next to it in trendy colors in a minimal style.
Venture capitalists
Tempero Raises $70M to Fight Substance Use Disorders
The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat alcohol- and cocaine-use disorders, among other indications.
March 24, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Vector illustration representing kidney care, highlighting the importance of health and medical attention for these vital organs
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
medical bottles isolated on blue background, drugs and
Mergers & acquisitions
Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M
Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic treatment Nuzyra.
March 20, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
A businessman jumps over a cliff. Art collage.
Patents
Just How Steep Is the Drug Patent Cliff? Ask These Pharmas
With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that have taken the leap off the patent cliff.
March 19, 2025
 · 
5 min read
 · 
Dan Samorodnitsky
Hand shake icon on wooden cube block which connection with human icon for business deal and agreement concept.
Deals
Servier Nabs Solid Tumor Asset in up to $780M Deal With Black Diamond
The French pharma is getting Black Diamond’s de-prioritized molecule for non-small cell lung cancers with specific mutations whose development had been paused to save money.
March 19, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Podcasts
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations without advisor input; Trump CDC nominee Dave Weldon pulled at last minute; and FDA decisions expected for Alnylam’s Amvuttra in ATTR-CM and Milestone’s etripamil in tachycardia.
March 19, 2025
 · 
2 min read
 · 
Heather McKenzie
Invest in best idea Investment and analysis money cash profits metaphor Flat tiny people and business concept for trading Economical wealth revenue visualized as growing on a tree vector illustration Field of Dreams
Gene editing
Arbor Raises $73.5M To Ride Out Gene Editing’s ‘Gartner Hype Cycle’
The gene therapy world is in turmoil, but Arbor, armed with more than $1 billion in partnerships and raises, is going forward.
March 18, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
A big businessman hands over the key to the house. Art collage, hand with keys.
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Vector illustration of a bottle of wine and a glass of wine on a yellow background in retro style.
GLP-1
Altimmune To Test Investigational GLP-1–Based Obesity Drug for Alcohol Use Disorder
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related conditions.
March 14, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
piggy bank behind umbrella to cover and protect from downturn arrow. Protection or defensive stock in economy crisis
Mergers & acquisitions
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy
The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an attempt to disrupt a merger with Alumis.
March 13, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Load More